FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2068291350> ?p ?o ?g. }

• W2068291350 endingPage "1346" @default.
• W2068291350 startingPage "1340" @default.
• W2068291350 abstract "Objective To investigate Port-A-Cath (PAC)-related thrombosis and postthrombotic syndrome (PTS) in children with cancer. Study design The study population was a consecutive cohort of children diagnosed with cancer and a PAC implanted at diagnosis. Children were evaluated for the presence of PAC-related thrombosis by magnetic resonance venography and the presence of congenital prothrombotic risk factors and PTS. Results A total of 114 children (median age, 6.04 years) were included. Of these children, 48 (42%) were treated for solid tumors and 66 (58%) were treated for hematopoietic tumors, including 38 for acute lymphoblastic leukemia. At the time of magnetic resonance venography, 42 children (37%) had the PAC still in place, and 72 (63%) had the PAC removed. Overall, PACs were in place for a total of 324.92 PAC-years. PAC-related thrombosis was detected in 45 children (39.5%) with a current or previous PAC. Of these, 21 (47%) had a solid tumor, 14 (31%) had acute lymphoblastic leukemia, and 10 (22%) had another hematopoietic tumor. Younger age at diagnosis, female sex, duration of PAC use, and left-side PAC placement were independently associated with an increased risk of thrombosis, whereas asparaginase therapy and the presence of inherited prothrombotic risk factors were not. Mild PTS (ie, presence of prominent collateral vessels in the skin) was present in 5.6% of the children. Conclusion PAC-related thrombosis is common in pediatric oncology patients. In some children, thrombotic complications can lead to the development of PTS. To investigate Port-A-Cath (PAC)-related thrombosis and postthrombotic syndrome (PTS) in children with cancer. The study population was a consecutive cohort of children diagnosed with cancer and a PAC implanted at diagnosis. Children were evaluated for the presence of PAC-related thrombosis by magnetic resonance venography and the presence of congenital prothrombotic risk factors and PTS. A total of 114 children (median age, 6.04 years) were included. Of these children, 48 (42%) were treated for solid tumors and 66 (58%) were treated for hematopoietic tumors, including 38 for acute lymphoblastic leukemia. At the time of magnetic resonance venography, 42 children (37%) had the PAC still in place, and 72 (63%) had the PAC removed. Overall, PACs were in place for a total of 324.92 PAC-years. PAC-related thrombosis was detected in 45 children (39.5%) with a current or previous PAC. Of these, 21 (47%) had a solid tumor, 14 (31%) had acute lymphoblastic leukemia, and 10 (22%) had another hematopoietic tumor. Younger age at diagnosis, female sex, duration of PAC use, and left-side PAC placement were independently associated with an increased risk of thrombosis, whereas asparaginase therapy and the presence of inherited prothrombotic risk factors were not. Mild PTS (ie, presence of prominent collateral vessels in the skin) was present in 5.6% of the children. PAC-related thrombosis is common in pediatric oncology patients. In some children, thrombotic complications can lead to the development of PTS." @default.
• W2068291350 created "2016-06-24" @default.
• W2068291350 creator A5003872799 @default.
• W2068291350 creator A5004135258 @default.
• W2068291350 creator A5038604161 @default.
• W2068291350 creator A5040190509 @default.
• W2068291350 creator A5047713774 @default.
• W2068291350 creator A5048985547 @default.
• W2068291350 creator A5084054061 @default.
• W2068291350 date "2013-11-01" @default.
• W2068291350 modified "2023-10-03" @default.
• W2068291350 title "Port-A-Cath–Related Thrombosis and Postthrombotic Syndrome in Pediatric Oncology Patients" @default.
• W2068291350 cites W104552217 @default.
• W2068291350 cites W1770147359 @default.
• W2068291350 cites W181091954 @default.
• W2068291350 cites W1968399105 @default.
• W2068291350 cites W1973447606 @default.
• W2068291350 cites W1974885634 @default.
• W2068291350 cites W1978645977 @default.
• W2068291350 cites W1987375545 @default.
• W2068291350 cites W1997936886 @default.
• W2068291350 cites W2005892362 @default.
• W2068291350 cites W2008678193 @default.
• W2068291350 cites W2016244973 @default.
• W2068291350 cites W2024181624 @default.
• W2068291350 cites W2030745749 @default.
• W2068291350 cites W2039487812 @default.
• W2068291350 cites W2045816462 @default.
• W2068291350 cites W2045967484 @default.
• W2068291350 cites W2058068548 @default.
• W2068291350 cites W2065121333 @default.
• W2068291350 cites W2078530277 @default.
• W2068291350 cites W2087661939 @default.
• W2068291350 cites W2095035824 @default.
• W2068291350 cites W2096146076 @default.
• W2068291350 cites W2109608564 @default.
• W2068291350 cites W2113013505 @default.
• W2068291350 cites W2117345900 @default.
• W2068291350 cites W2131737693 @default.
• W2068291350 cites W2139936875 @default.
• W2068291350 cites W2147865643 @default.
• W2068291350 cites W2148631711 @default.
• W2068291350 cites W2323876322 @default.
• W2068291350 cites W4324114385 @default.
• W2068291350 doi "https://doi.org/10.1016/j.jpeds.2013.06.076" @default.
• W2068291350 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23992671" @default.
• W2068291350 hasPublicationYear "2013" @default.
• W2068291350 type Work @default.
• W2068291350 sameAs 2068291350 @default.
• W2068291350 citedByCount "40" @default.
• W2068291350 countsByYear W20682913502014 @default.
• W2068291350 countsByYear W20682913502015 @default.
• W2068291350 countsByYear W20682913502016 @default.
• W2068291350 countsByYear W20682913502017 @default.
• W2068291350 countsByYear W20682913502018 @default.
• W2068291350 countsByYear W20682913502020 @default.
• W2068291350 countsByYear W20682913502021 @default.
• W2068291350 countsByYear W20682913502022 @default.
• W2068291350 countsByYear W20682913502023 @default.
• W2068291350 crossrefType "journal-article" @default.
• W2068291350 hasAuthorship W2068291350A5003872799 @default.
• W2068291350 hasAuthorship W2068291350A5004135258 @default.
• W2068291350 hasAuthorship W2068291350A5038604161 @default.
• W2068291350 hasAuthorship W2068291350A5040190509 @default.
• W2068291350 hasAuthorship W2068291350A5047713774 @default.
• W2068291350 hasAuthorship W2068291350A5048985547 @default.
• W2068291350 hasAuthorship W2068291350A5084054061 @default.
• W2068291350 hasConcept C121608353 @default.
• W2068291350 hasConcept C126322002 @default.
• W2068291350 hasConcept C141071460 @default.
• W2068291350 hasConcept C143998085 @default.
• W2068291350 hasConcept C187212893 @default.
• W2068291350 hasConcept C2778269268 @default.
• W2068291350 hasConcept C2780868729 @default.
• W2068291350 hasConcept C2908647359 @default.
• W2068291350 hasConcept C2993561819 @default.
• W2068291350 hasConcept C71924100 @default.
• W2068291350 hasConcept C90924648 @default.
• W2068291350 hasConcept C99454951 @default.
• W2068291350 hasConceptScore W2068291350C121608353 @default.
• W2068291350 hasConceptScore W2068291350C126322002 @default.
• W2068291350 hasConceptScore W2068291350C141071460 @default.
• W2068291350 hasConceptScore W2068291350C143998085 @default.
• W2068291350 hasConceptScore W2068291350C187212893 @default.
• W2068291350 hasConceptScore W2068291350C2778269268 @default.
• W2068291350 hasConceptScore W2068291350C2780868729 @default.
• W2068291350 hasConceptScore W2068291350C2908647359 @default.
• W2068291350 hasConceptScore W2068291350C2993561819 @default.
• W2068291350 hasConceptScore W2068291350C71924100 @default.
• W2068291350 hasConceptScore W2068291350C90924648 @default.
• W2068291350 hasConceptScore W2068291350C99454951 @default.
• W2068291350 hasIssue "5" @default.
• W2068291350 hasLocation W20682913501 @default.
• W2068291350 hasLocation W20682913502 @default.
• W2068291350 hasOpenAccess W2068291350 @default.
• W2068291350 hasPrimaryLocation W20682913501 @default.
• W2068291350 hasRelatedWork W2003938723 @default.
• W2068291350 hasRelatedWork W2016631605 @default.

• next